In analyzing the association between biologic-free remission maintenance and the type of biologic drugs that patients had used, a notable difference emerged between patients who used infliximab, adalimumab, or golimumab versus those who received etanercept and certolizumab pegol.
Some patients with rheumatoid arthritis (RA) are able to sustain clinical remission after discontinuing their treatment with biologics, but little is known about which biologics present the best chance for patients to do so.
The Kansai Consortium for Well-being of Rheumatic Disease Patients (ANSWER) cohort, an observational, multicenter registry of patients in Japan, offered an opportunity to assess which biologics are most advantageous for achieving biologic-free remission in a real-world setting. A research team retrospectively analyzed data from the ANSWER cohort from 2011 to 2016, and recently reported findings in Arthritis Research and Therapy.
A total of 1307 patients were part of the cohort, and serial disease activity data were available for 572 of them. The biologics taken by these patients comprised 4 groups: anti—tumor necrosis factor (anti-TNF) monoclonal antibodies (infliximab, adalimumab, and golimumab), soluble TNF receptor or Fab fragments against TNF (etanercept and certolizumab pegol), the fusion protein CTLA4–Ig (abatacept), and an anti–interleukin-6 agent (tocilizumab). Patients could also receive conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and glucocorticoids.
Among patients who discontinued biologics, 181 were in remission (defined as a disease activity score in a count of 28 joints with C-reactive protein of under 2.3). Biologic-free remission maintenance rates for this group were 21.5% at year 1 and 12.2% at year 2. The median duration until biologic-free remission failure was 70 days (range, 58-93).
Read more about treat-to-target strategies in RA.
In analyzing the association between remission maintenance and the type of biologic drugs that patients had used, a notable difference emerged between patients who used infliximab, adalimumab, or golimumab (n = 95) versus those who received etanercept and certolizumab pegol (n = 32); in the former group, remission was maintained for a median of 98 days (range, 70-178), while in the latter group, remission was maintained for a median of 63 days (range, 35-105). Those taking abatacept (n = 17) had a median maintenance period of 73 days (range, 35-245), and those taking tocilizumab (n = 37) had a median remission of 42 days (range, 29-56).
Clinical factors associated with biologic-free remission included a shorter disease duration (under 2 years), and biologic-naïve status at the time of starting the later-withdrawn biologic. If remission was maintained continuously for more than 6 months before withdrawing the biologic, patients were more likely to maintain that remission afterward. Using methotrexate at the time of biologic discontinuation decreased the risk of remission failure, while using glucocorticoids raised the risk of disease flares.
While biologic-free remission is difficult to achieve, conclude the authors, using infliximab, adalimumab, or golimumab, followed by abatacept, may offer patients the best advantage.
Reference
Hashimoto M, Furu M, Yamamoto W, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2018;20(1):165. doi: 10.1186/s13075-018-1673-1.
Switching From Originator Etanercept to Biosimilar Version Proves Safe, Effective in RA
September 5th 2024Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease activity and drug persistence compared with those who remained on the originator, indicating that nonmedical switching does not negatively impact treatment outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.